Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the July 2025 edition of ZERO's Prostate Cancer Discoveries Digest! We've gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Outcomes Study Shows Favorable Outcomes With Guideline-Based Treatment for Localized Prostate Cancer A large study showed the importance of treatment adherence for localized prostate cancer patients, who had favorable outcomes when following guideline-based care. » Full Article from Urology Times Treatment Final Analysis of ArtemisR, a European Retrospective Study of Apalutamide for Patients with mHSPC A European study found that patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus ADT experienced strong and rapid PSA responses, with many reaching very low PSA levels within the first year of treatment. » Full Article from BioMed Central Side Effects ACS Study Finds Early Palliative Care Remains Underused Among Patients With Advanced Cancer A study from earlier this year found that early supportive (palliative) care remains underused in patients with advanced cancer, despite clinical guidelines and strong evidence. » Full Article from ACS Genetics & Genomics Veterans' Decision Making for Prostate Cancer Germline Testing After Informed Consent With Their Oncologist: A Mixed-Methods Study A study of veterans with advanced prostate cancer found that while most agreed to germline genetic testing, many still lacked key information about testing. Recordings revealed oncologists often missed critical informed consent elements. » Full Article from ASCO Publications Outcomes Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors Among patients with metastatic prostate cancer taking androgen receptor signaling inhibitors (ARSIs), those with diabetes experienced higher rates of hospital or emergency care than patients without diabetes. » Full Article from ASCO Publications Health Equity Racial, Ethnic, Sex, And Age Representation In Clinical Trials Of Radiopharmaceutical Tumor Therapy: A Systematic Review And Meta-Analysis A new analysis of U.S.-based radiopharmaceutical therapy (RPT) trials found implications for prostate cancer, including emerging treatment options where Black men and older adults remain consistently underrepresented in trials. » Full Article from BioMed Central Diagnostics High-Throughput Ldi Ms Technology Decodes The Distinct Metabolic Landscape Of Prostate Cancer A new urine-based metabolic screening method using LDI-MS and machine learning showed high accuracy in distinguishing prostate cancer from benign conditions, offering promise for early, non-invasive diagnosis. » Full Article from Pub Med Central Diagnostics Plasma Epigenomic Profiling Reveals Treatment-Emergent Squamous Transformation In Prostate Cancer A case study reveals how liquid biopsy using epigenomic profiling of circulating chromatin can non-invasively detect rare treatment-resistant squamous transformation in prostate cancer, months before clinical diagnoses. » Full Article from Pub Med Central ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the July 2025 edition of ZERO's Prostate Cancer Discoveries Digest! We've gathered the latest headlines on prostate cancer treatment, diagnostics, side effects, and more—delivered straight to your inbox. Know someone who could benefit from these updates? Forward this newsletter and help spread the word. ZERO Prostate Cancer does not endorse any particular study or finding in this issue. Outcomes Study Shows Favorable Outcomes With Guideline-Based Treatment for Localized Prostate Cancer A large study showed the importance of treatment adherence for localized prostate cancer patients, who had favorable outcomes when following guideline-based care. » Full Article from Urology Times Treatment Final Analysis of ArtemisR, a European Retrospective Study of Apalutamide for Patients with mHSPC A European study found that patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with apalutamide plus ADT experienced strong and rapid PSA responses, with many reaching very low PSA levels within the first year of treatment. » Full Article from BioMed Central Side Effects ACS Study Finds Early Palliative Care Remains Underused Among Patients With Advanced Cancer A study from earlier this year found that early supportive (palliative) care remains underused in patients with advanced cancer, despite clinical guidelines and strong evidence. » Full Article from ACS Genetics & Genomics Veterans' Decision Making for Prostate Cancer Germline Testing After Informed Consent With Their Oncologist: A Mixed-Methods Study A study of veterans with advanced prostate cancer found that while most agreed to germline genetic testing, many still lacked key information about testing. Recordings revealed oncologists often missed critical informed consent elements. » Full Article from ASCO Publications Outcomes Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors Among patients with metastatic prostate cancer taking androgen receptor signaling inhibitors (ARSIs), those with diabetes experienced higher rates of hospital or emergency care than patients without diabetes. » Full Article from ASCO Publications Health Equity Racial, Ethnic, Sex, And Age Representation In Clinical Trials Of Radiopharmaceutical Tumor Therapy: A Systematic Review And Meta-Analysis A new analysis of U.S.-based radiopharmaceutical therapy (RPT) trials found implications for prostate cancer, including emerging treatment options where Black men and older adults remain consistently underrepresented in trials. » Full Article from BioMed Central Diagnostics High-Throughput Ldi Ms Technology Decodes The Distinct Metabolic Landscape Of Prostate Cancer A new urine-based metabolic screening method using LDI-MS and machine learning showed high accuracy in distinguishing prostate cancer from benign conditions, offering promise for early, non-invasive diagnosis. » Full Article from Pub Med Central Diagnostics Plasma Epigenomic Profiling Reveals Treatment-Emergent Squamous Transformation In Prostate Cancer A case study reveals how liquid biopsy using epigenomic profiling of circulating chromatin can non-invasively detect rare treatment-resistant squamous transformation in prostate cancer, months before clinical diagnoses. » Full Article from Pub Med Central ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
